• Introduction
• 16 min
  1. Psychopharmacology: structural aspects of the brain

  • Prof. Brian Leonard
• 66 min
  2. The nature of chemical neurotransmission

  • Prof. Brian Leonard
• 28 min
  3. Psychotropic drugs

  • Prof. Brian Leonard
• 26 min
  4. Psychopharmacology of anxiety disorders

  • Prof. Brian Leonard
• 35 min
  5. Psychopharmacology of depression

  • Prof. Brian Leonard
• 48 min
  6. Psychopharmacology of mania and schizophrenia

  • Prof. Brian Leonard
• 45 min
  7. The role of stress and immune system in psychiatric disorders

  • Prof. Brian Leonard
• Introduction to Genetic Investigations of Complex Traits
• 39 min
  8. Genetic association studies, TDT and the candidate gene approach

  • Dr. Jo Knight
• Genetics and Pharmacokinetics of Psychotropic Drugs
• 34 min
  9. Genetics of phase I enzymes

  • Prof. Aiming Yu
• 36 min
  10. Phase II metabolism

  • Prof. Ann Daly
• Genetics and Pharmacodynamics of Psychotropic Drugs
• 25 min
  11. Genetics and psychotropic drugs: present and future clinical applications

  • Dr. Chiara Fabbri
• 25 min
  12. Influence of neurotransmitter receptor variants on interactions with psychotropic drugs

  • Dr. Maria Arranz
• 51 min
  13. Pharmacogenetics of antidepressants

  • Prof. Alessandro Serretti
• Clinical Applications of Psychopharmacogenetics
• 41 min
  14. Of genes and drugs: genetic determinants of adverse drug reactions

  • Dr. Mario Masellis
• 35 min
  15. Cocaine and amphetamine addiction genetics

  • Dr. Gerome Breen
• 29 min
  16. Tailoring psychiatric treatment using genetic information: pharmacogenetic prediction of treatment response

  • Dr. Maria Arranz
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  17. Genetic, environmental and other design issues relevant for pharmacogenetics studies

  • Dr. Ridha Joober
• 37 min
  18. Genetic determinants of metabolism: clinical applications in psychiatry

  • Prof. Julia Stingl (formerly Kirchheiner)
• 36 min
  19. Rapid methods for the genetic determination of pharmacokinetic status

  • Dr. Paul Debenham
• 47 min
  20. Genetic polymorphisms influencing response to lithium

  • Prof. Alessandro Serretti
• 28 min
  21. Genetic determinants of antipsychotic-induced weight gain

  • Prof. Gavin Reynolds
• 59 min
  22. Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 1

  • Dr. Vincenzo Basile
• 50 min
  23. Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 2

  • Dr. Vincenzo Basile
• 37 min
  24. Genetic determinants of agranulocytosis

  • Dr. Michael Dettling
• 52 min
  25. Genetic polymorphisms influencing the response of antidepressants

  • Prof. Alessandro Serretti

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Pharmacogenetics
3. Factors implicated in PGx phenotypes modulation
4. Genetic factors and PGx phenotype variability
5. Different study designs provide PGx information
6. Genetic epidemiology
7. Familial aggregation studies
8. Familial resemblance - examples
9. Twin and adoption studies
10. Response to psychotropic drugs and heterogeneity
11. Psychotropic drugs and heterogeneity - example
12. PGx - a dynamic approach for behavioral genetics
13. Pharmaco-epidemiology and PGx phenotypes
14. Animal models
15. Conclusion (1)
16. Epidemiological evidence and methodology
17. Epidemiological evidence and biological pertinence
18. PGx phenotypes associated with better detectance
19. Different behaviors
20. Gene regulation of behavior
21. The effect of the same gene differs between subjects
22. Drug effect on gene modulation of behavior (1)
23. Drug effect on gene modulation of behavior (2)
24. Important factors to consider
25. Factors related to study design
26. Family based vs. case - control design
27. Placebo issues
28. Assessment issues
29. Observer effects
30. Sampling bias and PGx
31. Epidemiological issues of recruitment
32. Example: TD and severity of illness
33. Factors related to the subject
34. Adherence to treatment
35. Duration of illness
36. Age and Age at onset of the illness
37. Gender
38. Comorbid disorders
39. Factors related to other treatments of the patient
40. History of previous exposure to medications
41. Duration of untreated illness
42. Concomitant medication
43. Diet and smoking
44. First episode patients and pharmacogenetics
45. Conclusion (2)
46. Conclusion (3)

Topics Covered

• Definition of pharmacogenetics (PGx), pharmacokinetics and pharmacodynamics
• Modulation of PGx phenotypes
• Genetic factors play a role in determining the variability of PGx phenotypes
• Study design
• Genetic epidemiology
• Familial aggregation studies
• Twin and adoption studies
• Therapeutic response to psychotropic drugs
• Pharmaco-epidemiology and PGx phenotypes
• Animal models
• Balancing modest epidemiological evidence against biological pertinence
• Studying PGx phenotypes in relation to candidate genes
• Family-based vs. case control designs
• Observer effect
• Sampling bias
• Factors related to the subject

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Neuroscience
• Pharmaceutical Sciences

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Dr. Ridha Joober has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.